Prognosticators of Long-Term Outcomes of TNM Stage II Colorectal Cancer: Molecular Patterns or Clinicopathological Features

[1]  J. Pyo,et al.  Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer , 2019, The International journal of biological markers.

[2]  R. Wu,et al.  Prognostic value of microRNAs in colorectal cancer: a meta-analysis , 2018, Cancer management and research.

[3]  Hidetoshi Eguchi,et al.  MicroRNAs as Biomarkers in Colorectal Cancer , 2017, Cancers.

[4]  A. Avan,et al.  Therapeutic Potential of Targeting Wnt/β‐Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress , 2017, Journal of cellular biochemistry.

[5]  J. Albanell,et al.  Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Carethers.  Microsatellite Instability Pathway and EMAST in Colorectal Cancer , 2017, Current Colorectal Cancer Reports.

[7]  J. Guinney,et al.  Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.

[8]  Gong Chen,et al.  Association between Ki67 Index and Clinicopathological Features in Colorectal Cancer , 2016, Oncology Research and Treatment.

[9]  B. Glimelius,et al.  Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry , 2016, Acta oncologica.

[10]  Shung-Haur Yang,et al.  Mutation spectra of RAS gene family in colorectal cancer. , 2016, American journal of surgery.

[11]  Stephen B Gruber,et al.  Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer. , 2016, Journal of the National Cancer Institute.

[12]  G. Sauter,et al.  High Ki67 expression is an independent good prognostic marker in colorectal cancer , 2015, Journal of Clinical Pathology.

[13]  Jong Seob Park,et al.  Prognostic Comparison Between Mucinous and Nonmucinous Adenocarcinoma in Colorectal Cancer , 2015, Medicine.

[14]  Shung-Haur Yang,et al.  FBXW7 Mutation Analysis and its Correlation with Clinicopathological Features and Prognosis in Colorectal Cancer Patients , 2015, The International journal of biological markers.

[15]  Shung-Haur Yang,et al.  The prognostic role of microsatellite instability, codon‐specific KRAS, and BRAF mutations in colon cancer , 2014, Journal of surgical oncology.

[16]  K. Søreide,et al.  Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer , 2014, British Journal of Cancer.

[17]  Jae Hyuk Lee,et al.  Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. , 2013, American journal of surgery.

[18]  Aung Ko Win,et al.  KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers , 2013, British Journal of Cancer.

[19]  Thomas Rösch,et al.  Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer , 2013, Gut.

[20]  Ardavan Saeedi,et al.  The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis , 2012, PloS one.

[21]  Shung-Haur Yang,et al.  Lymphovascular invasion determines the outcome of stage I colorectal cancer patients , 2012 .

[22]  Y. Toiyama,et al.  Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. , 2012, Gastroenterology.

[23]  Shung-Haur Yang,et al.  Clinicopathologic features and prognostic analysis of MSI-high colon cancer , 2012, International Journal of Colorectal Disease.

[24]  D. Sargent,et al.  Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications , 2012, Clinical Cancer Research.

[25]  V. Lemmens,et al.  The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  S. Ramamoorthy,et al.  Relationship of EMAST and Microsatellite Instability Among Patients with Rectal Cancer , 2010, Journal of Gastrointestinal Surgery.

[27]  Sara M. Johnson,et al.  Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. , 2010, Journal of the American College of Surgeons.

[28]  Jong Hoon Kim,et al.  Prognostic Significance of Lymphovascular Invasion in Sporadic Colorectal Cancer , 2010, Diseases of the colon and rectum.

[29]  S. Gruber,et al.  Microsatellite instability in colorectal cancer—the stable evidence , 2010, Nature Reviews Clinical Oncology.

[30]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Boland,et al.  Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. , 2009, Oncology reports.

[32]  M. Bertagnolli,et al.  Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.

[33]  C. Ko,et al.  A 10-Year Outcomes Evaluation of Mucinous and Signet-Ring Cell Carcinoma of the Colon and Rectum , 2005, Diseases of the colon and rectum.

[34]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Behling,et al.  Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. , 2004, Gastroenterology.

[37]  James T. L. Mah,et al.  Incidence and Survival of Mucinous Adenocarcinoma of the Colorectum: A Population-Based Study From an Asian Country , 2004, Diseases of the colon and rectum.

[38]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[39]  R. Lothe,et al.  Portrait of the PI3K/AKT pathway in colorectal cancer. , 2015, Biochimica et biophysica acta.

[40]  V. Catalano,et al.  Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Jen‐Kou Lin,et al.  Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. , 2005, International journal of oncology.

[42]  Jen‐Kou Lin,et al.  Loss of Heterozygosity and DNA Aneuploidy in Colorectal Adenocarcinoma , 2003, Annals of Surgical Oncology.

[43]  G. Ranzani,et al.  Correspondence re: C.R. Boland et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58: 5248-5257, 1998 , 1999, Cancer research.

[44]  True Msi.  Correspondence re: C. R. Boland et al., A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer. Cancer Res., 58: 5248 -5257, 19 , 1999 .